Annual Cash & Cash Equivalents
$44.54 M
+$4.10 M+10.14%
December 31, 2022
Summary
- As of February 10, 2025, RVLP annual cash & cash equivalents is $44.54 million, with the most recent change of +$4.10 million (+10.14%) on December 31, 2022.
- During the last 3 years, RVLP annual cash & cash equivalents has fallen by -$51.32 million (-53.54%).
Performance
RVLP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$19.16 M
-$13.48 M-41.30%
June 30, 2023
Summary
- As of February 10, 2025, RVLP quarterly cash and cash equivalents is $19.16 million, with the most recent change of -$13.48 million (-41.30%) on June 30, 2023.
- Over the past year, RVLP quarterly cash and cash equivalents has dropped by -$8.25 million (-30.11%).
Performance
RVLP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RVLP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.1% | -30.1% |
| 3 y3 years | -53.5% | -86.3% |
| 5 y5 years | +28.2% | -32.6% |
RVLP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -9.2% | -67.9% | at low |
| 5 y | 5-year | -60.9% | -9.2% | -86.4% | -56.4% |
| alltime | all time | -60.9% | -56.1% | -86.4% | -56.4% |
RVL Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $19.16 M(-41.3%) |
| Mar 2023 | - | $32.64 M(-26.7%) |
| Dec 2022 | $44.54 M(+10.1%) | $44.54 M(-25.5%) |
| Sep 2022 | - | $59.75 M(+118.0%) |
| Jun 2022 | - | $27.41 M(+4.1%) |
| Mar 2022 | - | $26.34 M(-34.9%) |
| Dec 2021 | $40.44 M(-64.5%) | $40.44 M(+384.2%) |
| Sep 2021 | - | $8.35 M(-91.6%) |
| Jun 2021 | - | $99.78 M(-8.6%) |
| Mar 2021 | - | $109.21 M(-4.2%) |
| Dec 2020 | $114.05 M | $114.05 M(-9.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | $126.09 M(-10.2%) |
| Jun 2020 | - | $140.38 M(+11.6%) |
| Mar 2020 | - | $125.83 M(+31.3%) |
| Dec 2019 | $95.86 M(+35.3%) | $95.86 M(-2.2%) |
| Sep 2019 | - | $98.01 M(+53.8%) |
| Jun 2019 | - | $63.74 M(+1.1%) |
| Mar 2019 | - | $63.06 M(-11.0%) |
| Dec 2018 | $70.83 M(+103.9%) | $70.83 M(+120.0%) |
| Sep 2018 | - | $32.20 M(+13.4%) |
| Jun 2018 | - | $28.41 M(-18.2%) |
| Dec 2017 | $34.74 M(+77.6%) | $34.74 M |
| Dec 2016 | $19.56 M | - |
FAQ
- What is RVL Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for RVL Pharmaceuticals?
- What is RVL Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is RVL Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for RVL Pharmaceuticals?
- What is RVL Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is RVL Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of RVLP is $44.54 M
What is the all time high annual cash & cash equivalents for RVL Pharmaceuticals?
RVL Pharmaceuticals all-time high annual cash & cash equivalents is $114.05 M
What is RVL Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, RVLP annual cash & cash equivalents has changed by +$4.10 M (+10.14%)
What is RVL Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RVLP is $19.16 M
What is the all time high quarterly cash and cash equivalents for RVL Pharmaceuticals?
RVL Pharmaceuticals all-time high quarterly cash and cash equivalents is $140.38 M
What is RVL Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, RVLP quarterly cash and cash equivalents has changed by -$8.25 M (-30.11%)